Cargando…
Assessing patiromer utilization and associated serum potassium changes in US veterans with prior sodium polystyrene sulfonate exposure
Untreated chronic hyperkalemia is associated with an increased risk of mortality. Novel potassium binders (e.g., patiromer) are new additions to the clinician’s armamentarium. Prior to their approval, clinicians often considered trialing sodium polystyrene sulfonate. The study objective was to asses...
Autores principales: | Patel, Shardool, Pinnell, Derek, Qualls, Joshua, Rathod, Anitha, Chen, Wei, Boutin, Sylvie, Woods, Steven D., Kovesdy, Csaba P., Tangri, Navdeep, Sauer, Brian C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9981426/ https://www.ncbi.nlm.nih.gov/pubmed/36862858 http://dx.doi.org/10.1097/MD.0000000000033134 |
Ejemplares similares
-
Real-world evaluation of patiromer utilization and its effects on serum potassium in veterans with end stage kidney disease
por: Pinnell, Derek, et al.
Publicado: (2022) -
Justification for initiating patiromer when restricted by prior authorization and clinical guidance in a US health care system
por: Patel, Shardool, et al.
Publicado: (2022) -
Comparative efficacy of patiromer and sodium polystyrene sulfonate on potassium levels in chronic haemodialysis patients: a randomized crossover trial
por: Jaques, David A, et al.
Publicado: (2022) -
Clinical utility of patiromer, sodium zirconium cyclosilicate, and sodium polystyrene sulfonate for the treatment of hyperkalemia: an evidence-based review
por: Beccari, Mario V, et al.
Publicado: (2017) -
Clinical utility of patiromer, sodium zirconium cyclosilicate, and sodium polystyrene sulfonate for the treatment of hyperkalemia: an evidence-based review [Erratum]
Publicado: (2019)